News
DBVT
1.390
+2.96%
0.040
European Markets Move Higher Helped by Upbeat US Inflation Data
European Markets Move Higher Helped by Upbeat US Inflation Data
MT Newswires · 11/15 11:29
European ADRs Move Slightly Lower in Friday Trading
European ADRs Move Slightly Lower in Friday Trading
MT Newswires · 11/11 11:19
BRIEF-Dbv Technologies Reports Third Quarter Financial Results
Reuters · 11/03 21:12
DBV Technologies GAAP EPS of -$0.18, revenue of $2.07M
Seekingalpha · 11/03 20:49
DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...
GlobeNewswire · 10/31 20:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/25 21:41
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers
Benzinga · 09/28 16:40
Algoma Steel Group, Sandstorm Gold And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Wednesday. Here are some big stocks recording losses in today’s session.
Benzinga · 09/28 15:54
European ADRs Move Higher in Wednesday Trading
European ADRs Move Higher in Wednesday Trading
MT Newswires · 09/28 11:09
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.
Benzinga · 09/23 12:10
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers
Benzinga · 09/23 07:42
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
 Gainers
Benzinga · 09/22 16:26
Spero, HeartBeam top healthcare gainers; MediWound, Vincerx lead losers' pack
Gainers: Spero Therapeutics SPRO +135%. HeartBeam (BEAT) <font co...
Seekingalpha · 09/22 14:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday&#39;s pre-market session. The market value of their outstanding shares is at $64.1 million.
Benzinga · 09/22 12:19
European ADRs Move Lower in Thursday Trading
European ADRs Move Lower in Thursday Trading
MT Newswires · 09/22 11:30
FDA Slaps Partial Hold On DBV Technologies' Pivotal Trial Of Peanut Allergy Patch
Benzinga · 09/22 10:31
DBV Technologies Says FDA Placed Partial Clinical Hold on Phase 3 Study of Peanut Allergy Patch
DBV Technologies Says FDA Placed Partial Clinical Hold on Phase 3 Study of Peanut Allergy Patch
MT Newswires · 09/22 04:18
BRIEF-DBV Technologies Provides Clinical Update On Vitesse Phase 3 Trial
BRIEF-DBV Technologies Provides Clinical Update On Vitesse Phase 3 Trial
Reuters · 09/21 22:05
FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial
French biotech DBV Technologies (NASDAQ:DBVT) on Wednesday ...
Seekingalpha · 09/21 22:02
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial, FDA Places Partial Clinical Hold On Co.'s VITESSE Phase 3 Clinical Study
DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE
Benzinga · 09/21 21:46
More
Webull provides a variety of real-time DBVT stock news. You can receive the latest news about Dbv Technologies S A through multiple platforms. This information may help you make smarter investment decisions.
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.